CDK4/6 inhibitors in combination with endocrine treatment is associated with first-line treatment of metastatic estrogen receptor-positive (ER+) breast cancer. Dave Cescon, MD, PhD, Princess Margaret Cancer Centre, Toronto, Canada, discusses the challenge faced with treatment in the second-line setting due to common recurrence following first-line treatment. Circulating tumor DNA (ctDNA) is being utilized for the development of strategies to overcome mechanisms of resistance to CDK4/6 inhibitors. This interview took place at the European Society for Medical Oncology (ESMO) Breast Cancer 2022 congress in Berlin, Germany.

свернуть